Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1\2 clinical trial of Soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China.

Next Previous
Trial Profile

Phase 1\2 clinical trial of Soquelitinib for the treatment of patients with moderate-to-severe atopic dermatitis in China.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soquelitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Angel Pharmaceuticals; Corvus Pharmaceuticals

Most Recent Events

  • 02 Jul 2025 New trial record
  • 25 Jun 2025 According to Corvus Pharmaceuticals media release, patient recruitment for this trial expected in third quarter of 2025.Data from the Phase 1b portion available in 2026.
  • 25 Jun 2025 According to Corvus Pharmaceuticals media release, its partner Angel Pharmaceuticals Ltd. has received IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate this trial, and Dr. Yuling Shi will be the principle investigator of this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top